Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents

INTRODUCTION: Two doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high efficacy against symptomatic COVID-19, especially against the Omicron variant, but that can be improved by a third dose in adults. The use of a third dose of CoronaVac in adolescents may be supported by immunobrid...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Daniel, Cohen, Carolyn A., Mu, Xiaofeng, Rosa Duque, Jaime S., Cheng, Samuel M. S., Wang, Xiwei, Wang, Manni, Zhang, Wenyue, Zhang, Yanmei, Tam, Issan Y. S., Lam, Jennifer H. Y., Chan, Sau Man, Chaothai, Sara, Kwan, Kelvin K. H., Chan, Karl C. K., Li, John K. C., Luk, Leo L. H., Tsang, Leo C. H., Chu, Nym Coco, Wong, Wilfred H. S., Mori, Masashi, Leung, Wing Hang, Valkenburg, Sophie, Peiris, Malik, Tu, Wenwei, Lau, Yu Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026957/
https://www.ncbi.nlm.nih.gov/pubmed/36949953
http://dx.doi.org/10.3389/fimmu.2023.1106837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026957/
https://www.ncbi.nlm.nih.gov/pubmed/36949953
http://dx.doi.org/10.3389/fimmu.2023.1106837

Ejemplares similares